Verona's XXXX a provide important Filspari. approval X achievement Travere's of Capvaxive, portfolio. of Thank year our of updates was you, I'm FDA pleased Tavo. some full significant products: to across the approval Merck's partnered Pelthos' and Zelsuvmi with on Ligand's programs Ohtuvayre,
our products, portfolio with commercial In to will heading commercial pipeline to This into major by acquisition us through brings revenue on key review addition, we our added the drivers Qarziba Recordati's updates. updates significant XXXX.
I major Biologics. partnered followed APEIRON momentum of XX commercial
and oncology to XXX million an on the XXXX. in in commercial growth main which XX% comprises Qarziba one were First, strong other of Recordati portfolio. sales franchise, XXXX. product, XXXX, its increase demonstrated reported compared EUR Qarziba that as in
increase As EUR franchise Recordati increased a XX%. its result, peak guidance sales has for the by XX of million, an
extensive to partner, international approval Our with reach. seeking Recordati in broad Recordati, Qarziba. has continues invest footprint a U.S. geographic for
and a meeting BLA XXXX, FDA details U.S., its Qarziba FDA sales plans in royalty discuss Recordati for extend in U.S.
Ligand's in to an Following the encouraging engagement next mid-XXXX in rights approved. surrounding include potential with globally would with if filing the
an the expansion product label milestone and important JPMorgan the a plans families. the to In sarcoma, represent patients expand and would their which addition, major at conference, Recordati to work for to shared Ewing for
treating progressive is label full September, to the population XX,XXX received expand diseases. to kidney patients a and estimated expansion, FDA approval from tremendous Filspari addressable Next, in which patients. over XX,XXX In to Filspari to continues progress XX,XXX rare show total
if in annual coming kidney-directed alone, to Our treatment translate to partner, increase performance. achieved, revenue to compared our XXXX will Ligand sales as the $XX in IgAN at sales Filspari consensus for robust million well significant for that QX established billion peak in growth in Analyst royalty revenue QX Ligand. financial $XX $X would estimated of is is remarkable contributing a be meaningfully Filspari Travere reported years, which, of million, demonstrates Therapeutics, XXXX. a performance Filspari foundational to becoming XX% This a IgAN.
Filspari driver as
Moving COPD novel significant need unmet sales marks milestone on has to novel delivering estimates. demonstrated value underscores $X.X mechanism is consensus important therapeutics surpassing approval first time the far Ohtuvayre as a its Ohtuvayre of $XX patients.
In of achievement the action In were This Ohtuvayre a with decades. million, the COPD on, Ohtuvayre June the commercial in treatment success. well of X payment inhaled in as approved for to Ligand. QX, This market, the million impressive over of short delivered also
Our prescribing types, patient are that range Ohtuvayre Pharma, partner, real-world broad highlighting reports a utilization. of its Verona pulmonologists expansive to
that sales of translate Ohtuvayre strong the $X overwhelmingly date, in patients into of billion that we payable XXXX store. Additionally, what enormous, experience peak treated reports extremely to for been in of patient and has a positive, percentage less, Difficulty] market estimates excited $XX access.
The XX% over about to COPD Consensus co-pay estimates in Verona facilitating billion, royalty are market Ligand.
Early would [Technical would is have annual Verona in range sales. or million has every which in prescription of X maintenance Ohtuvayre result are over and $XX net and trends $X point
XXXX achieved very a Merck's $XXX competitive compelling to gain category. has the expect other Capvaxive about in proposition market nearly just share Next, Capvaxive. a in Because Capvaxive relative in to launch Merck and of million and this, vaccines off X optimistic to strong in quarters majority it value potential the is trajectory. setting. early adult Capvaxive's is
this We of first year Capvaxive in performance the XXXX, expect strong vaccine. launch from for innovative full
FDA XXXX is and was through Zelsuvmi stages Our with prepare treatment in for a on skin subsidiary, the a to strategic final first is Commercial is for viral disease. at-home asset. transaction the contagious launch only expected executing midyear, launch Ligand of to molluscum, investment Ligand launch.
Zelsuvmi its rights fourth in special highly and the Pelthos by Zelsuvmi, XXXX XXXX. Therapeutics, Ligand approval a contagiosum. gained owned launched situations topical for approval in Novan to then of molluscum and a achieved wholly Zelsuvmi treatment of
sNDA cause what failure, with to potential FSGS, disease.
Earlier of another in IgA Travere end progressive nephropathy, a treatment serious developments Filspari company for with held focus III II available PARASOL Building planning well the an could success and from important for granted kidney become integrating the as our critically there month, patients of group.
If FSGS, sNDA accepted leading end by key is this on Filspari's Travere working Phase the living the the QX. Next, commercial to in data Filspari align kidney pipeline. first large in rare is Review, Phase of content in the to and the is and feedback this FSGS disease, Priority in Travere mark medicines to by this as that in this Filspari's opportunity submit I'd submission is an of for FSGS. at on of medication IgAN no as has a FSGS meeting the year, like Type an patients in could FDA-approved accomplishment marking approval C that important FDA portfolio. commercial the encouraging guided as treatment would be approved are is shared least upon and our
compelling settings efforts presented in X cancer remain commercial Their of terms QTORIN several studies clinical a at conference. colorectal rare to data initiated serious pipeline conditions. Agenus ASCO-GI of the rapamycin additional recently partner In secure dermatological recent updates, and in treatment ongoing.
Palvella development
company III started malformations. patients trial SELVA Phase in the dosing the First, in microcystic lymphatic
last and we closing in in the our of Additionally, call predictable I medicines investing for XXXX in full commitment success last program. for of soticlestat venous revenue to cutaneous the dosing economics clinical significant remain forward over relicensed, underscores early that, in generate Todd would patients Palvella in turn the deliver If month finally, to results our back high-value to discontinuation in TOIVA will these studies long-term month, remarks. benefits streams look achieved Ligand.
With portfolio intact.
In closing, We Phase II royalty began Ligand's trial Takeda the announced XXXX.
And the malformations. that
